NM_000518.5:c.4G>A
Variant summary
Our verdict is Uncertain significance. Variant got 5 ACMG points: 6P and 1B. PM2PM5PP3_ModerateBP6
The NM_000518.5(HBB):c.4G>A(p.Val2Met) variant causes a missense change. The variant allele was found at a frequency of 0.00000624 in 1,443,092 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V2A) has been classified as Pathogenic.
Frequency
Consequence
NM_000518.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 5 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251128Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135724
GnomAD4 exome AF: 0.00000624 AC: 9AN: 1443092Hom.: 0 Cov.: 26 AF XY: 0.00000278 AC XY: 2AN XY: 719252
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not specified Uncertain:2
- -
Variant summary: HBB c.4G>A (p.Val2Met; also known as Hb South Florida) results in a conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 251128 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. The variant is known to interfere with some methods of HbA1c determination and has been (falsely) reported in several carriers as elevated HbA1c, but without clinical evidence of any hematologic abnormality (Shah 1986, Aslanger 2013, Celebiler 2014, Canatan 2016). These data indicate that this variant does not produce any clinical symptoms in heterozygous state. According to our knowledge, only one compound heterozygous individual has been reported in the literature who carried a pathogenic variant (c.92+1G>A) for beta-0-thalassemia in trans, and presented with beta-thalassemia trait without clinical manifestations (Tan 2006, Tan 2009). Since compound heterozygosity for two pathogenic variants would result in a more severe phenotype, this report provides supportive evidence for a benign role (Tan 2009). Early reports demonstrated that the variant prevents the cleavage of the initiator methionine (Boissel 1985), but does not result in an unstable hemoglobin (Shah 1986). However, to our knowledge no other studies performed further functional characterization, thus allowing no convincing conclusions about the variant effect. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, and classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as VUS-possibly benign. -
beta Thalassemia Uncertain:1Benign:1
- -
- -
not provided Benign:1
The Hb South Florida variant (HBB: c.4G>A; p.Val2Met, also known as Val1Met when numbered from the mature protein, rs33958358, HbVar ID: 713) is reported in the heterozygous state in asymptomatic individuals (Shah 1986). Additionally, it has been reported compound heterozygous with a pathogenic HBB variant in an individual presenting only with beta-thalassemia trait, suggesting a neutral effect for the Hb South Florida variant (Tan 2006 and 2009). Functional studies report this variant interferes with measurements of HbA1c (Boissel 1985, Shah 1986). This variant is reported in ClinVar (Variation ID: 15359). It is only found on one allele in the Genome Aggregation Database, indicating it is not a common polymorphism. Computational analyses predict that this variant is deleterious (REVEL: 0.82). Based on available information this variant is considered to be likely benign. References: Link to HbVar database: https://globin.bx.psu.edu/hbvar/menu.html Boissel JP et al. Amino-terminal processing of proteins: hemoglobin South Florida, a variant with retention of initiator methionine and N alpha-acetylation. Proc Natl Acad Sci U S A. 1985 Dec;82(24):8448-52. PMID: 3866233. Shah SC et al. Hemoglobin South Florida. New variant with normal electrophoretic pattern mistaken for glycosylated hemoglobin. Diabetes. 1986 Oct;35(10):1073-6. PMID: 3758492. Tan JA et al. Characterisation and confirmation of rare beta-thalassaemia mutations in the Malay, Chinese and Indian ethnic groups in Malaysia. Pathology. 2006 Oct;38(5):437-41. PMID: 17008283. Tan JA et al. Interaction of Hb South Florida (codon 1; GTG-->ATG) and HbE, with beta-thalassemia (IVS1-1; G-->A): expression of different clinical phenotypes. Eur J Pediatr. 2009 Sep;168(9):1049-54. PMID: 19034506. -
HEMOGLOBIN SOUTH FLORIDA Other:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at